<html><head>
<meta http-equiv="content-type" content="text/html; charset=windows-1252">
</head><body leftmargin="0" topmargin="0" alink="#ff6600" background="eegbiofeedbackadhd.php_files/bg.gif" bgcolor="#ffffff" link="#273e64" text="#000000" vlink="#273e64"><titleeeg biofeedback="" for="" adhd="" title="">
<meta http-equiv="Content-Type" content="text/html; charset=windows-1252">
<meta http-equiv="description" content="Important journal article reviewing the scientific evidence of EEG Biofeedback for ADHD.">
<meta http-equiv="keywords" content="attention-deficit/hyperactivity disorder, ADHD, EEG biofeedback, neurotherapy, efficacy, neurofeedback">
<meta name="robots" content="INDEX,FOLLOW">
<meta name="GOOGLEBOT" content="index,follow">
<meta name="revisit-after" content="14 Days">
<link href="eegbiofeedbackadhd.php_files/stylesheet.css" type="text/css" rel="stylesheet">
<link href="eegbiofeedbackadhd.php_files/menu_bar.css" type="text/css" rel="stylesheet">
<link href="eegbiofeedbackadhd.php_files/side_browser.css" type="text/css" rel="stylesheet">

<style type="text/css">
<!--
.style1 {color: #cc3300}
.style3 {color: #FFFF00}
.style4 {
	color: #0066cc;
	font-weight: bold;
}
-->
</style>



 
<table border="0" cellpadding="0" cellspacing="0" height="50" width="100%">    
    <tbody><tr> 
      <td lign="right" background="eegbiofeedbackadhd.php_files/back.gif" height="64" valign="top"><table border="0" cellpadding="0" cellspacing="0" width="100%">
        <tbody><tr>
          <td background="eegbiofeedbackadhd.php_files/back.gif" width="200"><a href="http://www.alertfocus.com/index.php"><img src="eegbiofeedbackadhd.php_files/logo.gif" alt="Home page" border="0" height="64" width="191"></a></td>
          <td background="eegbiofeedbackadhd.php_files/back.gif"><div align="right"><a href="http://www.alertfocus.com/index.php" class="whitelink">Home</a> 
              <span class="style3">|</span> <a href="mailto:garyames@alertfocus.com" class="whitelink">Email 
              me</a>&nbsp;&nbsp; </div></td>
        </tr>
      </tbody></table></td>       
    </tr>    
</tbody></table> 
<table bgcolor="#ffffff" border="0" cellpadding="0" cellspacing="0" width="100%">    
    <tbody><tr> 
      <td> <table bgcolor="#ffffff" border="0" cellpadding="0" cellspacing="0" width="100%">            
            <tbody><tr valign="top"> 
              <td bgcolor="#efefef" valign="top" width="199"> <table border="0" cellpadding="0" cellspacing="0" width="199">                    
                    <tbody><tr> 
                      <td><!-- SIDE NAV START --> 
                      
      
      <table align="center" border="0" cellpadding="0" cellspacing="0" width="100%">
      
      <tbody><tr>
          <td bgcolor="efefef" height="22">
            <img src="eegbiofeedbackadhd.php_files/crumb.png" align="absMiddle" border="0" height="11" width="19">
            <a href="http://www.alertfocus.com/wraparound/index.php" class="menu">Wrap around</a>
         </td>
      </tr>


<tr>
         <td bgcolor="white"><img src="eegbiofeedbackadhd.php_files/1px.gif" height="1" width="1"></td>
      </tr>
      
      <tr>
          <td bgcolor="efefef" height="22">
            <img src="eegbiofeedbackadhd.php_files/crumb.png" align="absMiddle" border="0" height="11" width="19">
            <a href="http://www.alertfocus.com/relieve/index.php" class="menu">Relieve</a>
         </td>
      </tr>


<tr>
<td bgcolor="efefef" height="22">
 <img src="eegbiofeedbackadhd.php_files/1px.gif" align="absMiddle" border="0" height="11" width="19">

    <img src="eegbiofeedbackadhd.php_files/crumb.png" align="absMiddle" border="0" height="11" width="19"> <a href="http://www.alertfocus.com/relieve/add/index.php" class="menu">ADD</a>
 </td>
      </tr>
<tr>
<td bgcolor="efefef" height="22">
 <img src="eegbiofeedbackadhd.php_files/1px.gif" align="absMiddle" border="0" height="11" width="19">

    <img src="eegbiofeedbackadhd.php_files/crumb.png" align="absMiddle" border="0" height="11" width="19"> <a href="http://www.alertfocus.com/relieve/autism/index.php" class="menu">Autism</a>
 </td>
      </tr>
<tr>
<td bgcolor="efefef" height="22">
 <img src="eegbiofeedbackadhd.php_files/1px.gif" align="absMiddle" border="0" height="11" width="19">

    <img src="eegbiofeedbackadhd.php_files/crumb.png" align="absMiddle" border="0" height="11" width="19"> <a href="http://www.alertfocus.com/relieve/additions/index.php" class="menu">Addictions</a>
 </td>
      </tr>
<tr>
<td bgcolor="efefef" height="22">
 <img src="eegbiofeedbackadhd.php_files/1px.gif" align="absMiddle" border="0" height="11" width="19">

    <img src="eegbiofeedbackadhd.php_files/crumb.png" align="absMiddle" border="0" height="11" width="19"> <a href="http://www.alertfocus.com/relieve/sleep/index.php" class="menu">Sleep</a>
 </td>
      </tr>
<tr>
<td bgcolor="efefef" height="22">
 <img src="eegbiofeedbackadhd.php_files/1px.gif" align="absMiddle" border="0" height="11" width="19">

    <img src="eegbiofeedbackadhd.php_files/crumb.png" align="absMiddle" border="0" height="11" width="19"> <a href="http://www.alertfocus.com/relieve/stress/index.php" class="menu">Stress</a>
 </td>
      </tr>
<tr>
<td bgcolor="efefef" height="22">
 <img src="eegbiofeedbackadhd.php_files/1px.gif" align="absMiddle" border="0" height="11" width="19">

    <img src="eegbiofeedbackadhd.php_files/crumb.png" align="absMiddle" border="0" height="11" width="19"> <a href="http://www.alertfocus.com/relieve/eating/index.php" class="menu">Eating</a>
 </td>
      </tr>
<tr>
<td bgcolor="efefef" height="22">
 <img src="eegbiofeedbackadhd.php_files/1px.gif" align="absMiddle" border="0" height="11" width="19">

    <img src="eegbiofeedbackadhd.php_files/crumb.png" align="absMiddle" border="0" height="11" width="19"> <a href="http://www.alertfocus.com/relieve/violence/index.php" class="menu">Criminal violence</a>
 </td>
      </tr>
<tr>
<td bgcolor="efefef" height="22">
 <img src="eegbiofeedbackadhd.php_files/1px.gif" align="absMiddle" border="0" height="11" width="19">

    <img src="eegbiofeedbackadhd.php_files/crumb.png" align="absMiddle" border="0" height="11" width="19"> <a href="http://www.alertfocus.com/relieve/migraine/index.php" class="menu">Migraine</a>
 </td>
      </tr>
<tr>
         <td bgcolor="white"><img src="eegbiofeedbackadhd.php_files/1px.gif" height="1" width="1"></td>
      </tr>
      
      <tr>
          <td bgcolor="efefef" height="22">
            <img src="eegbiofeedbackadhd.php_files/crumb.png" align="absMiddle" border="0" height="11" width="19">
            <a href="http://www.alertfocus.com/perform/index.php" class="menu">Perform</a>
         </td>
      </tr>


<tr>
<td bgcolor="efefef" height="22">
 <img src="eegbiofeedbackadhd.php_files/1px.gif" align="absMiddle" border="0" height="11" width="19">

    <img src="eegbiofeedbackadhd.php_files/crumb.png" align="absMiddle" border="0" height="11" width="19"> <a href="http://www.alertfocus.com/perform/sales/index.php" class="menu">Sales Training</a>
 </td>
      </tr>
<tr>
<td bgcolor="efefef" height="22">
 <img src="eegbiofeedbackadhd.php_files/1px.gif" align="absMiddle" border="0" height="11" width="19">

    <img src="eegbiofeedbackadhd.php_files/crumb.png" align="absMiddle" border="0" height="11" width="19"> <a href="http://www.alertfocus.com/perform/executive/index.php" class="menu">Executive</a>
 </td>
      </tr>
<tr>
<td bgcolor="efefef" height="22">
 <img src="eegbiofeedbackadhd.php_files/1px.gif" align="absMiddle" border="0" height="11" width="19">

    <img src="eegbiofeedbackadhd.php_files/crumb.png" align="absMiddle" border="0" height="11" width="19"> <a href="http://www.alertfocus.com/perform/sports/index.php" class="menu">Sports</a>
 </td>
      </tr>
<tr>
<td bgcolor="efefef" height="22">
 <img src="eegbiofeedbackadhd.php_files/1px.gif" align="absMiddle" border="0" height="11" width="19">

    <img src="eegbiofeedbackadhd.php_files/crumb.png" align="absMiddle" border="0" height="11" width="19"> <a href="http://www.alertfocus.com/perform/academic/index.php" class="menu">Academic</a>
 </td>
      </tr>
<tr>
<td bgcolor="efefef" height="22">
 <img src="eegbiofeedbackadhd.php_files/1px.gif" align="absMiddle" border="0" height="11" width="19">

    <img src="eegbiofeedbackadhd.php_files/crumb.png" align="absMiddle" border="0" height="11" width="19"> <a href="http://www.alertfocus.com/perform/military/index.php" class="menu">Military</a>
 </td>
      </tr>
<tr>
         <td bgcolor="white"><img src="eegbiofeedbackadhd.php_files/1px.gif" height="1" width="1"></td>
      </tr>
      
      <tr>
          <td bgcolor="#E2F1E2" height="22">
            <img src="eegbiofeedbackadhd.php_files/crumb.png" align="absMiddle" border="0" height="11" width="19">
            <a href="http://www.alertfocus.com/evidence/index.php" class="menu">Evidence</a>
         </td>
      </tr>


<tr>
         <td bgcolor="white"><img src="eegbiofeedbackadhd.php_files/1px.gif" height="1" width="1"></td>
      </tr>
      
      <tr>
          <td bgcolor="efefef" height="22">
            <img src="eegbiofeedbackadhd.php_files/crumb.png" align="absMiddle" border="0" height="11" width="19">
            <a href="http://www.alertfocus.com/about/index.php" class="menu">About</a>
         </td>
      </tr>


<tr>
         <td bgcolor="white"><img src="eegbiofeedbackadhd.php_files/1px.gif" height="1" width="1"></td>
      </tr>
      
      <tr>
          <td bgcolor="efefef" height="22">
            <img src="eegbiofeedbackadhd.php_files/crumb.png" align="absMiddle" border="0" height="11" width="19">
            <a href="http://www.alertfocus.com/links/index.php" class="menu">Links</a>
         </td>
      </tr>


<tr>
         <td bgcolor="white"><img src="eegbiofeedbackadhd.php_files/1px.gif" height="1" width="1"></td>
      </tr>
      
      <tr>
          <td bgcolor="efefef" height="22">
            <img src="eegbiofeedbackadhd.php_files/crumb.png" align="absMiddle" border="0" height="11" width="19">
            <a href="http://www.alertfocus.com/contact/index.php" class="menu">Contact</a>
         </td>
      </tr>


<tr>
         <td bgcolor="white"><img src="eegbiofeedbackadhd.php_files/1px.gif" height="1" width="1"></td>
      </tr>
            </tbody></table>
      <!-- èíôîðìàöèÿ î êîðçèíå þçåðà-->
      <br><br>
                      <!-- SIDE NAV END --></td> 
                    </tr> 
                    <tr> 
                      <td>&nbsp;</td> 
                    </tr>    
                    
                                   
                </tbody></table>              </td> 
              <td bgcolor="#d8d8d8" width="1">
              <img src="eegbiofeedbackadhd.php_files/zero.gif" height="5" width="1">
              </td> 
              <td bgcolor="#ffffff" valign="top" width="100%"> 
              
              <table bgcolor="#f7f7f7" border="0" cellpadding="0" cellspacing="0" width="100%"> 
                      <tbody><tr> 
                        <td align="left" bgcolor="#efefef" height="22"><table border="0" cellpadding="0" width="100%">
                    <tbody><tr> 
                      <td class="crumbs"><img src="eegbiofeedbackadhd.php_files/1px.gif" height="15" width="10"> <a href="http://www.alertfocus.com/index.php" class="menu">Home</a>   &gt; <a href="http://www.alertfocus.com/evidence/index.php" class="menu">Evidence</a>  
                      </td>
                      <td class="smallfont3"> 
                        <div align="right"><a class="menu" href="http://www.alertfocus.com/evidence/eegbiofeedbackadhd.php?print=1">Printer-friendly version</a> </div></td>
                    </tr>
                  </tbody></table> </td>
                      </tr> 
                      <tr> 
                              <td align="left" bgcolor="#cccccc">
                              <img src="eegbiofeedbackadhd.php_files/1px.gif" height="1" width="180"></td> 
                </tr> 
                </tbody></table> 
                <table border="0" cellpadding="0" cellspacing="0" width="100%"> 
                   
                    <tbody><tr> 
                      <td valign="top" width="100%"> <table class="page" border="0" cellpadding="15" width="100%">
                        <tbody><tr>
                          <td class="page" valign="top"><table border="0" cellpadding="0" cellspacing="0" width="100%">
                          <tbody><tr> 
                            <td valign="top"><div class="title style1">EEG Biofeedback for ADHD</div> 
                            </td>
                          </tr>
                        </tbody></table>                          
                            <br>
                            <div class="border smallfont3"> Important journal article reviewing the scientific evidence of EEG Biofeedback for ADHD.</div>
                            <br>                            
<p><span class="page"></span></p><p><strong>Applied Psychophysiology and Biofeedback</strong>, Vol. 30, No. 2, June 2005 ( C_ 2005)<br>DOI: 10.1007/s10484-005-4305-x<br><strong>Electroencephalographic Biofeedback in the Treatment<br>of Attention-Deficit/Hyperactivity Disorder</strong><br>Vincent J. Monastra,1,2,7 Steven Lynn,2 Michael Linden,3 Joel F. Lubar,4<br>John Gruzelier,5 and Theodore J. LaVaque6<br></p>
<p><em>Historically, pharmacological treatments for attention-deficit/hyperactivity disorder<br>(ADHD) have been considered to be the only type of interventions effective for reducing<br>the core symptoms of this condition. However, during the past three decades, a series of<br>case and controlled group studies examining the effects of EEG biofeedback have reported<br>improved attention and behavioral control, increased cortical activation on quantitative<br>electroencephalographic examination, and gains on tests of intelligence and academic<br>achievement in response to this type of treatment. This review paper critically examines the<br>empirical evidence, applying the efficacy guidelines jointly established by the Association<br>for Applied Psychophysiology and Biofeedback (AAPB) and the International Society for<br>Neuronal Regulation (ISNR). On the basis of these scientific principles, EEG biofeedback<br>was determined to be “probably efficacious” for the treatment of ADHD. Although significant<br>clinical improvement was reported in approximately 75% of the patients in each of<br>the published research studies, additional randomized, controlled group studies are needed<br>in order to provide a better estimate of the percentage of patients with ADHD who will<br>demonstrate such gains in clinical practice.<br></em>KEY WORDS: attention-deficit/hyperactivity disorder; ADHD; EEG biofeedback; neurotherapy; efficacy;<br>review.<br>INTRODUCTION<br>Attention-Deficit/Hyperactivity Disorder is an enduring mental disorder, characterized<br>by persistent symptoms of inattention alone or in combination with hyperactivity and<br>impulsivity (American Psychiatric Association, 1994). Prevalence of this disorder in the<br>United States is reported to be approximately 7% (Gadow &amp; Sprafkin, 1997; Pelham,<br>1FPI Attention Disorders Clinic, Endicott, New York.<br>2Binghamton University, Binghamton, New York.<br>3ADD Treatment Centers, San Juan Capistrano, California.<br>4University of Tennessee, Memphis, Tennessee.<br>5Imperial College, London, United Kingdom.<br>6The Stress Clinic, Green Bay, Wisconsin.<br>7Address all correspondence to Vincent J. Monastra, PhD, FPI Attention Disorders Clinic, 2102 E. Main St.,<br>Endicott, New York 13760; e-mail: <a href="mailto:drmonastra@stny.rr.com">drmonastra@stny.rr.com</a>.<br>&nbsp;<br>1090-0586/05/0600-0095/0 C_ 2005 Springer Science+Business Media, Inc.</p>
<p>Gnagy, Greenslade, &amp; Milich, 1992; Wolraich, Hannah, Pinnock, Baumgaertel, &amp; Brown,<br>1996) with international prevalence rates ranging from 2 to 29% (Barkley, 1998). The<br>severity of these symptoms is known to significantly impair a person’s ability to function<br>effectively at home, school, and in the workplace.<br>Without effective treatment, children and adolescents with ADHD are at greater risk<br>to develop academic, behavioral, mood, and anxiety disorders (Biederman et al., 1996),<br>incur accidental injury (Hartsough &amp; Lambert, 1985; Lahey et al., 1998), and struggle with<br>substance abuse disorders (Claude &amp; Firestone, 1995; Mannuzza et al., 1991). Similarly,<br>when not systematically treated, adults with a childhood history of ADHD have academic<br>histories marked by lower average marks, more expulsions, a higher rate of retention in<br>a grade, and fewer completed grades (Weiss &amp; Hechtman, 1993; Mannuzza et al., 1993,<br>1998). These patients are more likely to have a higher incidence of substance abuse,<br>psychiatric disorders, and criminal behavior, and have an employment history of more jobs,<br>more frequent “layoffs” and an overall job status that was lower than that of peers of similar<br>intelligence without ADHD (Weiss &amp; Hechtman, 1993; Murphy &amp; Barkley, 1996).<br>Because of the severity and enduring nature of the functional impairments associated<br>with ADHD, a substantial amount of scientific effort has been directed at understanding the<br>causes of ADHD and the identification of effective treatments. Beginning with the early<br>clinical impressions of Still (1902) and Tredgold (1908), researchers have wondered if<br>children with problems of behavioral inhibition and lack of sustained attention suffered from<br>some type of undiagnosed brain disease or injury. Over the past century, the preponderance<br>of scientific findings now supports the position that ADHD is an inherited disorder, whose<br>core symptoms are founded in neuroanatomical, neurochemical, and neurophysiological<br>characteristics that adversely affect neuronal functioning at the cortical level.<br>GENETICS, NEUROANATOMY, AND ADHD<br>During the past decade, numerous scientific studies of twins have revealed a heritability<br>index of approximately .75 for ADHD (Levy, Hay, McStephen, Wood, &amp; Waldman, 1997;<br>Silberg et al., 1996; Willcut, Pennington, &amp; DeFries, 2000). Similarly elevated incidence<br>rates are evident in studies of families including a member with ADHD. In families that<br>include a child with ADHD, over 30% of the siblings also have ADHD (Biederman et al.,<br>1992; Biederman, Keenan &amp; Faraone, 1990; Welner, Welner, Stewart, Palkes, &amp; Wish,<br>1977). In those families that include an adult with ADHD, the likelihood that at least one<br>child will have this disorder is 57% (Biederman et al., 1995).<br>Efforts to identify those genes that contributed to these patterns of inheritance have<br>focused primarily on dopaminergic alleles. This appears to be due to recent advances in<br>molecular biology, which has revealed that stimulant medications produce their clinical<br>effects by occupying dopamine reuptake transporters, thereby increasing the availability of<br>dopamine at the synaptic level (Ding et al., 1997; Volkow et al., 1995). In genetic studies<br>conducted to date, there is evidence implicating that anomalies of the dopamine receptor-<br>4 gene (DRD4: Smalley et al., 1998), the dopamine receptoer-2 gene (DRD2; Comings<br>et al., 1996), and the dopamine reuptake transporter (DAT1) gene (Cook et al., 1995) occur<br>significantly more frequently in patients with ADHD. The hypothesis derived from these<br>studies was that such anomalies would limit the number of dopamine receptors and result<br>in reduction of the size of dopamine-rich brain regions.<br>Neuroanatomical studies of patients with ADHD supported such a hypothesis by<br>providing evidence of structural differences between patients with ADHD and healthy age<br>peers. Because the core symptoms of ADHD are comprised of impaired behavioral control<br>and lack of sustained attention, neuroimaging studies have focused on those structures<br>involved in the control of movement (e.g. the basal ganglia and the cerebellum) and<br>attentional functions (e.g. the anterior cingulate gyrus, the right frontal region, the anterior<br>and posterior regions of the corpus callosum, and the caudate). As would be anticipated<br>on the basis of genetic findings, reports of reduced size in each of these regions has been<br>reported and replicated in the scientific literature (Aylward et al., 1996; Castellanos, 1997;<br>Castellanos et al., 1994; Giedd et al., 1994; Hynd, Hern, Novey, &amp; Eliopulos, 1993; Hynd,<br>Semrud-Clikeman, Lorys, &amp; Novey, 1990; Mostofsky, Reiss, Lockhart, &amp; Denckla, 1998;<br>Semrud-Clikeman, Filipek, Biederman, &amp; Steingard, 1994).<br>Further indication of the significance of the prefrontal cortex, the basal ganglia circuitry,<br>and the cerebellum in regulating attention and behavioral control is evident in<br>the results of studies utilizing single photon emission tomography (SPECT) and positron<br>emission tomography (PET). Initially, Lou, Henriksen, and Bruhn (1984) reported hypoperfusion<br>in the prefrontal cortex and basal ganglia during PET examination of patients<br>with ADHD. Subsequently, Zametkin et al. (1990) and Ernst et al. (1994) reported decreased<br>glucose metabolism in these regions, indicating cortical underarousal. Researchers<br>using SPECT imaging (e.g. Kim, Lee, Shin, Cho, &amp; Lee, 2002; Sieg, Gaffney, Preston, &amp;<br>Hellings, 1995) likewise noted decreased cerebral blood flow in the right lateral prefrontal<br>cortex, the right middle temporal cortex, and the orbital and cerebellar cortices (bilaterally)<br>in patients diagnosed with ADHD.<br>QUANTITATIVE ELECTROPHYSIOLOGY AND ADHD<br>Consistent with the results of neuroimaging studies, neurophysiological researchers<br>have primarily found evidence of underactivity over frontal and central, midline cortical<br>regions in approximately 85–90% of patients with ADHD (Chabot, Merkin, Wood,<br>Davenport, &amp; Serfontein, 1996; Clarke, Barry, McCarthy, &amp; Selikowitz, 2001a; Mann,<br>Lubar, Zimmerman, Miller, &amp; Nuenchen, 1992; Monastra et al., 1999). The primary electrophysiological<br>indicators of underactivity that have been identified via quantitative electroencephalographic<br>(QEEG) analysis of patients with ADHD include: elevated relative<br>theta power, reduced relative alpha and beta power, and elevated theta/alpha and theta/beta<br>power ratios, predominately over frontal and central, midline regions.<br>A secondary pattern of excessive activity or “hyperarousal” over frontal regions has<br>also been revealed in patients with ADHD (e.g. Chabot &amp; Serfontein, 1996; Clarke, Barry,<br>McCarthy, &amp; Selikowitz, 2001b). This pattern has been particularly evident in those patients<br>who have not responded optimally to stimulant medications (Chabot, Orgill, Crawford,<br>Harris, &amp; Serfontein, 1999). In such patients, QEEG analysis has revealed increased relative<br>beta power, decreased relative alpha power, and decreased theta/beta power ratios across<br>all cortical recording sites in comparison to healthy peers.<br>Additionally, when compared to other patients diagnosed with ADHD, patients with<br>“hyperaroused” profiles demonstrated greater relative beta activity, decreased relative theta<br>activity, decreased theta/beta ratios, and decreased relative delta over frontal and central<br>regions of the cortex. Although it is not clear whether those “ADHD” patients who <br>demonstrate cortical hyperarousal constitute a different clinical syndrome, EEG biofeedback<br>protocols have been developed to treat ADHD patients who present with either<br>hypoarousal or hyperarousal over frontal or central midline regions.<br>THE RATIONALE FOR EEG BIOFEEDBACK FOR ADHD<br>The rationale for EEG biofeedback is derived from substantial neurophysiological<br>research which clarified the relationship between surface EEG and the underlying thalamocortical<br>mechanisms that are responsible for its rhythms and frequency modulations. As<br>reviewed by Sterman (1996), variations in alertness and behavioral control appear directly<br>related to specific thalamocortical generator mechanisms and that such variations are evident<br>in distinctive EEG frequency rhythms that emerge over specific topographic regions of<br>the brain. He hypothesized that neuropathology (such as ADHD) could alter these rhythms<br>and that EEG feedback training directed at normalizing these rhythms may yield sustaining<br>clinical benefits. Consistent with this hypothesis, each of the large scale QEEG studies of<br>patients with ADHD that have been conducted since 1996 (e.g. Chabot et al., 1996; Chabot<br>&amp; Serfontein, 1996; Clarke et al., 2001a, 2001b; Clarke, Barry, McCarthy, &amp; Selikowitz,<br>1998; Monastra et al., 1999; Monastra, Lubar, &amp; Linden, 2001) has reported abnormal<br>QEEG findings in patients with ADHD.<br>Further impetus for the development of EEG biofeedback for ADHD is derived from<br>studies demonstrating adverse side effects and insufficient response to existing medical<br>treatments. Although both stimulant (e.g. methylphenidate, dextroamphetamine and pemoline)<br>and nonstimulant medications (e.g. atomoxetine and impramine) have been shown<br>to be efficacious for the treatment of the core symptoms of ADHD in controlled, group<br>studies, approximately 25% of ADHD patients demonstrate either an adverse response or<br>no response (Greenhill, Halperin, &amp; Abikoff, 1999; Swanson, McBurnett, Christian, &amp;<br>Wigel, 1995). In addition, as noted by Pelham and Murphy (1986), only a minority of<br>ADHD patients show sufficient improvement to be considered within the normal range<br>following medication treatments and there is great variability in the degree of improvement<br>noted in those patients who do respond to medication (Pelham &amp; Smith, 2000). Typically<br>improvements are noted in some functional domains but not in others. As concluded by<br>Pelham (2002), “other interventions are needed for nonresponders or incomplete responders<br>to medication” (pp. 12–13).<br>TREATMENT PROTOCOLS<br>As previously noted, the vast majority of patients diagnosed with ADHD demonstrate<br>excessive cortical slowing during QEEG, PET, or SPECT examinations. A smaller<br>percentage exhibit cortical “hyperarousal.” During the past three decades, specific EEG<br>biofeedback treatments that target cortical slowing or hyperarousal have been developed<br>and evaluated in controlled case and group studies. In each of these studies, patients have<br>participated in training procedures in which they were reinforced (via tone or visual display)<br>for producing a specific change in cortical activity (e.g. reducing the amplitude of<br>activity at slower EEG frequencies; increasing activity in faster frequencies). Typically, the<br>patient had to maintain this desired change for a period of 0.5 s in order to be “rewarded.”<br>It was hypothesized that if patients could begin to “normalize” the level of activity in<br>regions responsible for attention and behavioral control, they would begin to demonstrate<br>developmentally appropriate abilities to attend and maintain behavioral control.<br>The initial demonstration that biofeedback could yield changes in cortical activity and<br>that such modifications resulted in observable improvements in behavior/functioning was<br>provided by Sterman and his colleagues (Sterman, Wywricka, &amp; Roth, 1969; Wywricka &amp;<br>Sterman, 1968). Much of Sterman’s groundbreaking research examined the electrophysiological<br>characteristics of behavioral inhibition (Roth, Sterman, &amp; Clemente, 1967; Sterman<br>&amp; Wywricka, 1967; Wywricka &amp; Sterman, 1968). His methodical examination of EEG<br>patterns associated with inhibition led to the identification of the “Sensorimotor Rhythm”<br>(or SMR), which is generated over the Rolandic Cortex. Although initially identified as a<br>range of activity between 12 and 20 cycles per second, the “peak activity” of the SMR was<br>noted at 12–14 Hz. Sterman et al. (1969) and Wywricka and Sterman (1968) found that<br>laboratory animals could be trained to produce this rhythm voluntarily and applied these<br>findings in the treatment of individuals with a specific type of impaired behavioral control<br>(epilepsy). As reviewed by Sterman (2000) and Monastra (2003), this application of EEG<br>biofeedback has been demonstrated to be particularly helpful in the treatment of seizure<br>disorders in patients who have not responded to pharmacological treatments.<br>The initial application of SMR training for the treatment of patients with ADHD<br>was reported by Lubar and Shouse (1976). Their initial demonstration of clinical response<br>in a hyperactive child stimulated considerable interest in SMR training as a potentially<br>efficacious treatment for ADHD. Subsequently, in response to scientific understanding of<br>the role of the frontal lobes in sustained attention, and mounting evidence of excessive<br>cortical slowing over central, midline and frontal regions in ADHD patients, Lubar and<br>his colleagues (e.g. Lubar &amp; Lubar, 1984) expanded their EEG biofeedback treatments to<br>include efforts to increase production of EEG activity in a faster frequency range (“beta”:<br>16–20 Hz), while suppressing activity at slower speeds (“theta”: 4–8 Hz). These two primary<br>training approaches (SMR enhancement; theta suppression/beta enhancement) provide the<br>foundation for each of the protocols that have been examined in the controlled group studies<br>of EEG biofeedback in the treatment of ADHD conducted to date. Although recent QEEG<br>findings of a neurophysiological “subtype” of ADHD patients, characterized by excessive<br>“beta” activity over frontal regions (Chabot &amp; Serfontein, 1996: Clarke et al., 2001a,<br>2001b), have prompted interest in the development of protocols to suppress excessive beta<br>appearing frontally, no controlled group studies examining this type of EEG biofeedback<br>have been reported to date.<br>At this time, three EEG biofeedback treatment protocols have been primarily examined<br>in controlled-group studies. Reflecting neuroanatomical findings, these protocols target<br>cortical regions responsible for attention and behavioral inhibition. A brief description of<br>each follows:<br>PROTOCOL 1: SMR ENHANCEMENT/THETA SUPPRESSION<br>In this type of EEG biofeedback, patients are encouraged to develop control over<br>behaviors of hyperactivity and impulsivity by learning to increase their production of the<br>SMR (12–15 Hz) over one of two sites (C3 or C4), while simultaneously suppressing the<br>production of theta (4–7 or 4–8 Hz) activity. Typically, recordings are obtained from one<br>active site, referenced to linked earlobes, with a sampling rate of at least 128 Hz. Auditory<br>(tones) and visual feedback (counter display; movement of puzzle pieces, graphic designs,<br>or animated figures) is provided based on patient success in controlling microvolts of theta<br>or SMR, or the percentage of time that theta is below or SMR is above (SMR) pretreatment<br>“thresholds.” This type of training was included in the first controlled, group study of EEG<br>biofeedback for ADHD (Rossiter &amp; LaVaque, 1995).<br>PROTOCOL 2: SMR ENHANCEMENT-BETA-2 SUPPRESSION<br>A secondary type of SMR training has also been examined in a controlled, group study<br>(Fuchs, Birbaumer, Lutzenberger, Gruzelier, &amp; Kaiser, 2003). In this protocol, patients<br>with ADHD, Predominately Hyperactive-Impulsive Type are trained to increase SMR (12–<br>15 Hz) activity, while simultaneously decreasing beta-2 (22–30 Hz) activity. Recordings<br>are obtained at C4 with linked ear reference. Sampling rate is at least 128 Hz. In Fuchs<br>et al.’s protocol, patients with a Combined Type of ADHD receive this type of training<br>during half of each session. During the other half of each session, a theta suppression beta-<br>1 enhancement protocol (described below) is followed (training site: C3). As with the<br>“first” SMR protocol, feedback is contingent on patient success in controlling microvolts<br>of theta, SMR, beta-1 or beta-2.<br>PROTOCOL 3: THETA SUPPRESSION/BETA-1 ENHANCEMENT<br>This protocol has been investigated in three of the five controlled, group studies<br>published to date (Linden, Habib, &amp; Radojevic, 1996; Monastra, Monastra, &amp; George,<br>2002; Rossiter &amp; LaVaque, 1995). In this training procedure, patients are encouraged to<br>increase production of beta-1 activity (16–20 Hz), while suppressing theta activity (4–<br>8 Hz). Recordings are obtained at Cz with linked ear reference (monopolar); at FCz-PCz<br>with ear reference, or at Cz-Pz with ear reference. Fuchs et al. (2003) used a variation of<br>this protocol with patients diagnosed with ADHD, Predominately Inattentive Type, training<br>theta suppression and beta enhancement at C3. Sampling rate is at least 128 Hz. Feedback<br>is provided contingent on patient success in controlling microvolts of beta or theta.<br>A combination of two of these procedures (Protocol 1 and 3) has also been reported in<br>a controlled, group study (Carmody, Radvanski, Wadhwani, Sabo, &amp; Vergara, 2001). In this<br>procedure, patients are encouraged to increase production of a restricted range of beta-1<br>activity (16–18 Hz) while suppressing activity at 2–7 Hz. Recordings are obtained at C3<br>or Cz with linked ear reference (monopolar). Students who displayed increased aggression<br>or agitation within the first 13–35 sessions of this type of training were considered to be<br>“overstimulated.” Such patients were then treated with a SMR training protocol, in which<br>they were reinforced for increasing activity at 13–15 Hz and suppressing activity at 2–7 Hz.<br>REVIEW OF THE SCIENTIFIC LITERATURE: CASE STUDIES<br>As noted in reviews by Lubar (2003) and Monastra (2003), there are numerous case<br>studies demonstrating clinical benefits in patients diagnosed with ADHD. Historically,<br>training has followed Protocol 1 or Protocol 3, with slight variation in the size of the<br>SMR or theta bands. The initial report (Lubar &amp; Shouse, 1976) presented the results of<br>an SMR training protocol (Protocol 1) in the treatment of an 11-year-old boy diagnosed<br>with hyperkinesis. In their study, Lubar and Shouse demonstrated an electrophysiological<br>&nbsp;<br>Table I. Summary of the Primary Findings of Studies Examining the Efficacy of EEG Biofeedback for the<br>Treatment of ADHD: Selected Case Studies<br>Participants Method Sessions Outcome<br>Researchers N Ages Dx Design Protocol N/week Total QEEG Beh. CPT<br>Lubar &amp; Shouse (1976) 1 11 H 1 1 3 158 (+) (+) (+)<br>Lubar et al. (1995) 17 8–15 C 0 2 5 30–45 (+) NR NR<br>Thompson &amp; Thompson 111 5–63 I/H/C 0 1, 3 2 40 (+) NR (+)<br>(1998)<br>Kaiser &amp; Othmer (2000) 186 5–67 I/H/C 0 1a 1–5 20–40+ NR NR (+)<br>Heywood &amp; Beale (2003) 7 7–12 I/H/C 2 1 NR 80 NR (+*) NR<br>Note. (+): statistically significant change in score on dependent measure; (+*): statistically significant change<br>only among participants who completed treatment; NR: not reported. Dx code: I = ADHD, predominately<br>inattentive; H = ADHD, predominately hyperactive; C = ADHD, combined; design: 0 = Single/multiple case<br>study, repeated measurement; 1 = Single/multiple case study, ABAB (Reversal); 2 = Single/multiple case Study,<br>ABAB (Reversal) with placebo control.<br>aVariation of SMR enhancement/theta suppression protocol.<br>training effect in the laboratory that was associated with a decrease in off-task and oppositional<br>behaviors, as well as, increased cooperation and completion of school work in<br>the classroom. By using an ABA case study design, Lubar and Shouse showed that these<br>clinical gains paralleled patient increases and decreases in control over SMR activity during<br>training sessions.<br>Since the publication of this initial case study, there have been other notable case<br>reports, the most extensive being Thompson and Thompson’s (1998) study of 111 patients<br>diagnosed with Attention Deficit Disorder (with and without hyperactivity) and Kaiser and<br>Othmer’s (2000) investigation of EEG biofeedback in 1089 patients (186 diagnosed with<br>ADHD). Clinical gains included improved scores on tests of attention and impulse control<br>(Kaiser &amp; Othmer, 2000; Thompson &amp; Thompson, 1998), as well as, an average increase<br>of 12 points on the Wechsler Full Scale Intelligence Quotient (Thompson &amp; Thompson).<br>Table I summarizes the characteristics of several important case-studies.<br>Initial reports of the enduring nature of EEG biofeedback have been provided by<br>Tansey (1993) and Lubar (2003). Tansey (1993) reported the results of a 10-year follow-up<br>study, which indicated that a child (initially treated in the fourth grade) was able to maintain<br>sustained control over hyperactive symptoms during adolescence and early adulthood.<br>Lubar (2003) conducted a retrospective study of 52 patients who had completed EEG<br>biofeedback treatment for ADHD over a 10-year period. During telephone interviews conducted<br>by an independent surveyor, parents (or older patients) were asked to rate the degree<br>of improvement in 16 targeted symptoms (e.g. fidgeting, restlessness, overactivity, inattention,<br>failure to complete tasks, outbursts of temper, low frustration tolerance, relationships<br>with others) since the completion of treatment. The results of the survey were positive,<br>with primary improvements noted in sustained control over symptoms of hyperactivity,<br>emotional lability, rate of completing homework, and report card marks.<br>CRITIQUE OF CASE STUDIES<br>As in any field of applied clinical research, case studies are necessary in the development<br>of new treatments. Through such studies, researchers are able to identify potentially<br>beneficial intervention strategies, as well as, any potential patient risks. Such is the case<br>with EEG biofeedback for ADHD. During the last 25 years, several training protocols have<br>been developed and examined in case studies using a variety of procedures to determine<br>treatment effects. Examination of the outcomes of these case studies reveals consistently<br>positive results. Each of the studies reported to date indicated improvements in symptoms<br>of attention and behavioral control in patients diagnosed with hyperkinesis or ADHD<br>(Inattentive; Hyperactive-Impulsive; or Combined Types) following treatment with EEG<br>Biofeedback. No significant adverse effects were reported in the case studies, although<br>deterioration of clinical effects and relapse has been reported in those case studies in which<br>training has been discontinued prior to completion of treatment (e.g. Lubar &amp; Shouse,<br>1976).<br>Despite the positive outcomes reported in case studies, information derived from such<br>studies is considered insufficient to demonstrate the efficacy of any treatment (Chambless<br>&amp; Hollon, 1998; LaVaque et al., 2002; Nuwer, 1997). Although meta-analysis studies have<br>concluded that there is often no difference in terms of outcome between the results of case controlled<br>and prospective-randomized studies (Benson &amp; Hartz, 2000), case studies do not<br>provide a method for examining nonspecific factors that may influence the effectiveness of<br>a particular treatment in applied clinical settings.<br>In evaluating the efficacy of any type of treatment, it is important to use research<br>designs that can clarify the degree that beneficial effects are due to factors other than the<br>specific treatment that was administered (in this case, EEG biofeedback). Such nonspecific<br>factors include therapist characteristics (e.g. degree of compassion, understanding,<br>displayed knowledge or confidence), patient characteristics (e.g. patient intelligence and<br>capacity to learn new skills, severity of the disorder, the degree of hope or expectancy, variations<br>in patient motivation for participating in the study), and treatment characteristics (e.g.<br>the administration of a pill; the use of computerized EEG equipment), patient exposure to<br>other therapeutic experiences, other than the treatment under investigation (e.g. counseling,<br>tutoring, variations in parenting styles), and maturation. Without controls for such factors,<br>the percentage of patients likely to respond to any treatment is difficult to estimate.<br>Two controlled, case studies can serve to illustrate the importance of motivation and<br>capacity to learn new skills in assessing efficacy. In the mid-1990’s Lubar and his colleagues<br>reported the outcome of a series of studies, including one examining the efficacy<br>of EEG biofeedback (Lubar, Swartwood, Swartwood, &amp; Timmerman, 1995). In studying<br>the effects of theta suppression/beta enhancement (Protocol 3) in 17 children diagnosed<br>with ADHD, these researchers reported that two groups emerged. One group of children<br>(n = 6) were unable to demonstrate a training effect on any of the EEG measures obtained<br>during training. Another group (n = 11) was able to “learn” to increase cortical activation<br>(by lowering the theta/beta power ratio). Although the association between learning to<br>control cortical activation via EEG biofeedback and degree of clinical response was not<br>directly assessed, Lubar et al.’s (1995) paper illustrates the importance of directly assessing<br>neurophysiological indicators of learning in any evaluation of the efficacy of EEG<br>biofeedback.<br>Heywood and Beale’s (2003) more recent study of EEG biofeedback in seven children<br>diagnosed with ADHD provides further impetus for examining such nonspecific factors. In<br>their study, they provided a “bona fide” biofeedback training protocol designed to promote<br>an increase of SMR and decrease in theta and beta 2 at Cz. The placebo control training<br>included “noncontingent” EEG biofeedback in which a series of randomly determined<br>bandwidths were reinforced or inhibited (e.g. 12–29 Hz; 2–6 Hz; 2–18 Hz). In addition,<br>Heywood and Beale (2003) used a randomized design with an embedded ABAB reversal, to<br>control for maturation and treatment sequence effects. Children were not informed whether<br>the training was bona fide or placebo.<br>Examination of their findings revealed that five of the children completed training,<br>two did not. Analysis of results indicated that when the data were analyzed for children<br>who completed treatment, a significant positive effect was noted on neurophysiological<br>and behavioral measures of attention. However, when the data from the two children<br>who discontinued treatment were included, and control for overall trend was added to<br>the analysis, the overall size of these gains diminished. Although it is difficult to draw<br>conclusions regarding the efficacy of EEG biofeedback from such a small study, Heywood<br>and Beale’s work illustrates the importance of reporting the results of “nonresponders” and<br>controlling for nonspecific factors and trend effects in studies examining the efficacy of<br>EEG biofeedback.<br>Overall, the results of case studies illustrate the potential benefits of EEG biofeedback<br>in the treatment of patients with ADHD. However, it is clear from a review of case studies<br>that there is a percentage of patients who will not “learn” how to regulate cortical activity<br>and reduce core ADHD symptoms via EEG biofeedback. In reported case studies, that<br>percentage is comparable to the number of patients who do not respond to stimulant<br>medications and ranged from 29% (Heywood &amp; Beale, 2003) to 35% (Lubar et al., 1995).<br>In addition, the results of the Heywood and Beale (2003) study provides evidence that<br>nonspecific factors (e.g. expectancy, maturation) need to be evaluated/controlled in efficacy<br>studies of EEG biofeedback for ADHD.<br>REVIEW OF THE SCIENTIFIC LITERATURE:<br>CONTROLLED-GROUP STUDIES<br>To date, five controlled-group studies have been reported in peer-reviewed journals<br>(Carmody et al., 2001; Fuchs et al., 2003; Linden et al., 1996; Monastra et al., 2002; Rossiter<br>&amp;LaVaque, 1995) [see Table II]. Each of these studies sought to examine the effects of EEG<br>biofeedback in the treatment of patients diagnosed with ADHD, while attempting to control<br>for certain factors (e.g. age, intelligence, severity of symptoms prior to initiating treatment).<br>Table II. Summary of the Primary Findings of Studies Examining the Efficacy of EEG Biofeedback for the<br>Treatment of ADHD: Controlled Group Studies<br>Participants Method Sessions Outcome<br>Researchers N Ages Dx Design Protocol N/week Total QEEG Beh. CPT<br>Rossiter &amp; LaVaque 46 8–21 I/C 1 1,3 3–5 20 NR (+) (+)<br>(1995)<br>Linden et al. (1996) 18 5–15 I/H/C 0 3 2 40 NR (+) (+)<br>AD/LD<br>Carmody et al. (2001) 16 8–10 I/H/C/N 0 1, 3a 3–4 36–48 (-) (+) (+)<br>Monastra et al. (2002) 100 6–19 I/C 1 3 1 34–50 (+) (+) (+)<br>Fuchs et al. (2003) 34 8–12 I/H/C 1 2 3 36 NR (+) (+)<br>Note. (+): statistically significant change in score on dependent measure; (-): no statistically significant change<br>in score on dependent measure; NR: not reported. Dx code: I = ADHD, predominately inattentive; H = ADHD,<br>predominately hyperactive; C = ADHD combined; AD/LD = ADHD + learning disorder; N = No psychiatric<br>disorder. design: 0 = controlled group study, random assignment, waiting list control; 1 = Controlled group<br>study, nonrandom assignment, bona fide treatment comparison (stimulants).<br>aVariation of theta/suppression/SMR and beta enhancement protocols.<br>Maturation effects were also controlled in each of these studies and comparisons with a<br>“bona fide” treatment that has been classified as efficacious (i.e. stimulant medication) were<br>included in three of the five studies in order to control for placebo and trend effects.<br>The first of the controlled studies was published by Rossiter and LaVaque (1995).<br>This study sought to compare the effects of EEG biofeedback and stimulant medication<br>(methylphenidate or dextroamphetamine) on a continuous performance test (Test of<br>Variables of Attention, Greenberg &amp; Dupuy, 1993) and a standardized behavioral rating<br>scale which assessed ADHD symptoms, as well as indicators of other types of behavioral<br>problems (Behavior Assessment System for Children). After initial pretesting, patients<br>were matched for age, intelligence, gender, and diagnosis and treated with one of two<br>EEG biofeedback protocols (Protocol 1 or Protocol 3) or with stimulant medication (as<br>prescribed, monitored, and adjusted by the patient’s physician). A total of 46 patients<br>(aged 8–21) participated in the study. Two groups of 23 patients received the treatment of<br>their (or parent’s) choice (either medication or 20 sessions of EEG biofeedback). Patients<br>participating in EEG biofeedback were seen three to five times per week (45–50-min<br>sessions that included 30 min of feedback)<br>The results of this study indicated significant improvement on the T.O.V.A. and several<br>subscales of the BASC (e.g. Hyperactivity, Attention Problems, and Externalizing<br>Behaviors) in patients who completed EEG biofeedback. In addition, comparison with a<br>bona fide treatment for ADHD (stimulant medication) revealed no difference in the efficacy<br>of these treatments after 20 sessions. Similarly, there was no significant difference in the<br>percentage of patients who showed significant improvement with EEG biofeedback (83%)<br>and stimulant medication (87%).<br>The second published controlled group study was reported by Linden et al. (1996).<br>In this study, 18 children (ages 5–15) diagnosed with ADHD were randomly assigned to<br>either a “waiting list” condition (and received no psychological treatment or medication)<br>or EEG biofeedback (Protocol 3). Groups were comprised of an equal number of children<br>diagnosed with ADHD alone (n = 6) or in combination with a learning disorder (n = 3),<br>for a total of nine children in each group. Power analysis conducted prior to initiating the<br>study indicated sufficient sample size to detect significant group statistical differences. The<br>study was conducted over a six month time period. Patients receiving EEG biofeedback<br>participated in 40, 45-min training sessions. Medications for ADHD were not prescribed.<br>The results of the Linden et al. (1996) study reflected a significant increase on a<br>measure of intelligence (Kaufman Brief Intelligence Scale: Kaufman &amp; Kaufman, 1990)<br>and a reduction in symptoms of inattention on the IOWA-Conners Behavior Rating Scale<br>in the group of children who received EEG biofeedback. No adverse results were reported.<br>A randomized, waiting list, controlled group study was also conducted by Carmody<br>et al. (2001) in a school setting. In their study, 16 children (ages 8–10) were randomly<br>assigned to an active treatment condition (EEG biofeedback) or a waiting list. Eight of the<br>children were diagnosed with ADHD; eight were not diagnosed with ADHD or any other<br>psychiatric disorder. Although pharmacological treatment had been recommended for all<br>of the children diagnosed with ADHD, none of their parents selected that type of treatment.<br>Carmody et al. (2001) utilized a variation of Protocols 1 and 3 in their study. During<br>the active phase of treatment, participants received 3–4 EEG biofeedback sessions<br>per week, completing between 36 and 48 sessions during a six month period. Dependent<br>variables of interest included several QEEG measures (“delta-theta” amplitude; beta amplitude;<br>SMR amplitude), home and school versions of a behavioral rating scale assessing<br>frequency of ADHD symptoms (ADDES; McCarney, 1989) and a continuous performance<br>test (T.O.V.A., Greenberg &amp; Dupuy, 1993).<br>The results of the Carmody et al. (2001) study indicated that children with ADHD<br>who were treated with EEG biofeedback reduced symptoms of impulsivity on the T.O.V.A.<br>and were rated as more attentive by their teachers on the School Version of the ADDES.<br>However, no consistent pattern of improvement was evident on the QEEG measures selected<br>by this research team.<br>Monastra et al. (2002) published the largest, controlled-group study in the literature.<br>Similar to Rossiter and LaVaque (1995), the effects of EEG biofeedback were compared<br>with a “bona fide” treatment (Ritalin). In their study, 100 patients (aged 6–19) participated in<br>a multimodal treatment program that included: stimulant medication (dosage titrated based<br>on the results of behavioral measures and the T.O.V.A.), a 10 week parenting program<br>(Monastra, 2004) with subsequent, individualized parent-counseling provided as needed,<br>and academic support at school (via an Individual Education Plan or 504 Accommodation<br>Plan). Patients were also given the opportunity to receive EEG biofeedback (Protocol 3)<br>as part of their treatment program. Fifty-one families chose to include EEG biofeedback<br>(49 did not). The average dose of Ritalin administered to the patients of both groups was<br>25 mg (10 mg after breakfast, 10 mg after lunchtime, 5 mg after school). The range was<br>15–45 mg per day.<br>EEG biofeedback sessions were conducted on a weekly basis (45–50 min) and continued<br>until the patient could demonstrate a level of cortical activity on the QEEG scan<br>that was within 1.0 standard deviation of age peers (Monastra et al., 1999 database) and<br>could maintain this level of arousal for three consecutive, training sessions (40 min each).<br>The average number of sessions needed to reach this goal was 43 (range 34–50). All of the<br>participants who received EEG biofeedback achieved this goal.<br>Pretreatment screening included tests of intelligence, behavioral rating scales, a continuous<br>performance test, and a QEEG assessment (Monastra et al., 1999). All of the<br>participants needed to demonstrate evidence of cortical slowing on the QEEG measure in<br>order to be included in the study. There were no significant differences on pretreatment<br>measures between patients who received EEG biofeedback as part of their treatment and<br>those who did not.<br>Posttreatment evaluation was conducted 1 year after initial evaluation, under two<br>conditions. First, participants were evaluated while continuing to take stimulant medication.<br>Subsequent to this assessment, medication was discontinued for 1 week, and participants<br>were evaluated following this medication “wash-out.” All participants remained in the study<br>for the year required to complete this research.<br>Results of the Monastra et al. (2002) study supported the efficacy of stimulant medication<br>as well as EEG biofeedback, and indicated that parenting style was a moderating<br>factor in both treatments. In their study, significant improvement was noted in both groups<br>on posttreatment evaluations that were conducted while the patients were using medication.<br>However, following a week-long medication wash-out, relapse was noted on behavioral and<br>CPT measures in each of the participants who had not received EEG biofeedback and no<br>sustained improvement was noted on the QEEG measure among the members of that group.<br>In contrast, patients who received EEG biofeedback as part of their treatment demonstrated<br>sustained improvement on the T.O.V.A. and on behavioral measures, and maintained<br>gains on QEEG measures of cortical arousal even when tested after a 1-week medication<br>washout. In both the EEG biofeedback and the “non-biofeedback” groups, parents who <br>were systematically using the strategies taught in the parenting program had children who<br>displayed fewer attentional and behavioral control problems at home.<br>The fifth controlled-group study was reported by Fuchs et al. (2003). In this study,<br>a comparison between EEG biofeedback and a bona fide treatment for ADHD (stimulant<br>medication) was investigated. A total of 34 children (aged 8–12) participated in the study.<br>Twelve were treated with Ritalin (mean dose: 10 mg, t.i.d.; Range: 10–60 mg per day).<br>Neurofeedback sessions (Protocol 2) were conducted three times per week (30–60 min in<br>duration). All participants were treated for a 12-week period. Assignment to the treatment<br>groups was based on parental preference.<br>As with the other controlled-group studies, pretreatment measures included a test of<br>intelligence (WISC-R), computerized tests of attention (T.O.V.A.; the Attention Endurance<br>Test, Brickenkamp, 1994), and behavioral rating scales (IOWA-Conners Behavior Rating<br>Scale). Statistical analysis of pretreatment measures indicated that the groups were<br>comparable in terms of intelligence and severity of impairment associated with ADHD.<br>Posttreatment analysis revealed that both EEG biofeedback and Ritalin were associated<br>with significant improvements on computerized tests of attention and on behavioral rating<br>scales. The degree of improvement noted in patients treated with EEG biofeedback was<br>comparable with that noted in patients treated with Ritalin. No adverse effects were reported.<br>CRITIQUE OF CONTROLLED-GROUP STUDIES<br>Controlled-group studies of EEG biofeedback in the treatment of ADHD have demonstrated<br>beneficial effects of EEG biofeedback on measures of intelligence, on behavioral<br>ratings scales assessing the frequency of the core symptoms of ADHD, on computerized<br>tests of attention, and on QEEG measures of cortical arousal. In contrast to case-studies,<br>these studies have compared patient outcomes obtained following EEG biofeedback training<br>with those noted following a bona fide treatment of ADHD (stimulant medication),<br>as well as a waiting list control. These consistent reports of significant, beneficial effects<br>in controlled, group studies following the use of a nonpharmacological treatment (EEG<br>biofeedback), represents a significant step in the identification of effective psychological<br>treatments for ADHD. To date, no other type of psychological treatment has been<br>demonstrated to exert a significant effect on the core symptoms of ADHD (i.e. inattention,<br>hyperactivity, and impulsivity).<br>Despite the positive results of studies examining the efficacy of EEG biofeedback,<br>data from controlled-group studies that randomly assign participants to EEG biofeedback<br>or comparison groups (e.g., stimulant medication, noncontingent biofeedback, or a waiting<br>list control group that has comparable amount of therapist contact) are needed in order to<br>clarify the percentage of patients diagnosed with ADHD who will respond to EEG biofeedback<br>in clinical practice. Although the studies reported to date have indicated a positive<br>response in over 75% of patients treated with EEG biofeedback, these studies have been<br>conducted by highly experienced therapists, with patients who volunteered to receive this<br>type of treatment. As such, the number of “treatment responders” and the degree of clinical<br>improvement reported in these studies may exceed results obtained in clinical practice.<br>As noted previously, differences in patient characteristics (e.g. motivation for change,<br>expectancy or hope that a new treatment will “work,” interest in learning new skills) and<br>in therapist characteristics (e.g. degree of compassion, understanding of protocols, level of<br>confidence displayed in sessions, ability to conduct treatment sessions with a high degree <br>of fidelity) can affect response to treatment. Randomized, controlled-group studies that<br>monitor and control for such factors are still needed. Such studies will facilitate a better<br>understanding of the percentage of patients likely to respond to EEG biofeedback for<br>ADHD in clinical practice.<br>ASSESSMENT OF EFFICACY<br>The Guidelines for Evaluation of Clinical Efficacy of Psychophysiological Interventions<br>(LaVaque et al., 2002), which have been accepted by the Association for Applied<br>Psychophysiology &amp; Biofeedback (AAPB) and the International Society for Neuronal<br>Regulation (ISNR), specify five types of classification for the effectiveness of biofeedback<br>procedures, ranging from “Not empirically supported” to “Efficacious and Specific.” The<br>requirements for each classification level is summarized below.<br>Criteria for Levels of Evidence of Efficacy<br>Level 1: Not empirically supported. This classification is assigned to those treatments that<br>have only been described and supported by anecdotal reports and/or case studies in<br>non-peer reviewed journals.<br>Level 2: Possibly efficacious. This classification is considered appropriate for those treatments<br>that have been investigated in at least one study that had sufficient statistical<br>power, well identified outcome measures, but lacked randomized assignment to a control<br>condition internal to the study.<br>Level 3: Probably efficacious. Treatment approaches that have been evaluated and shown<br>to produce beneficial effects in multiple observational studies, clinical studies, wait list<br>control studies, and within-subject and between-subject replication studies merit this<br>classification.<br>Level 4: Efficacious. In order to be considered “efficacious,” a treatment must meet the<br>following criteria:<br>(a) In a comparison with a no-treatment control group, alternative treatment group,<br>or sham (placebo) control utilizing randomized assignment, the investigational<br>treatment is shown to be statistically significantly superior to the control condition<br>or the investigational treatment is equivalent to a treatment of established<br>efficacy in a study with sufficient power to detect moderate differences;<br>(b) The studies have been conducted with a population treated for a specific problem,<br>from whom inclusion criteria are delineated in a reliable, operationally<br>defined manner;<br>(c) The study used valid and clearly specified outcome measures related to the<br>problem being treated;<br>(d) The data are subjected to appropriated data analysis;<br>(e) The diagnostic and treatment variables and procedures are clearly defined in a<br>manner that permits replication of the study by independent researchers, and<br>(f) The superiority or equivalence of the investigational treatment have been shown<br>in at least two independent studies” (LaVaque et al., 2002, p. 280).<br>Level 5: Efficacious and Specific. To meet the criteria for this classification, the treatment<br>needs to be demonstrated to be statistically superior to a credible sham therapy, pill, or<br>bona fide treatment in at least two independent studies.<br>Review of the scientific literature revealed both controlled case and group studies on<br>the effects of EEG biofeedback in treating the core symptoms of ADHD. These studies<br>examined the efficacy of well-defined treatment protocols in the treatment of patients diagnosed<br>with hyperkinesis, as well as, those diagnosed with each of the primary subtypes of<br>ADHD (Inattentive, Hyperactive-Impulsive, or Combined). The results of these studies indicated<br>improvement on standardized tests of intelligence, attention, and behavioral control<br>following EEG biofeedback. Increased level of cortical arousal was also reported during<br>QEEG examination of patients treated with EEG biofeedback. Comparisons with a bona<br>fide treatment for ADHD (stimulant medication) indicated that EEG biofeedback yielded<br>equivalent or superior results. The results of randomized, controlled group studies using<br>a waiting list control also indicated the superiority of EEG biofeedback. Such findings<br>suggest the efficacy of EEG biofeedback in the treatment for ADHD.<br>However, because of the small sample size in the two, randomized group studies<br>reported, and the absence of control for patient and therapist characteristics that could<br>influence outcome in any of the five, controlled-group studies, our determination (based<br>on AAPB/ISNR Guidelines) is that EEG biofeedback is probably efficacious for the treatment<br>of ADHD. Although it is clear from the outcomes of each of the published case<br>and controlled studies of EEG biofeedback for ADHD, that significant, beneficial effects<br>have consistently been reported in patients/families who volunteered to receive this type<br>of treatment, additional controlled, group studies (with random assignment to treatment<br>condition) are needed in order to promote a clearer understanding of the number of patients<br>and degree of improvement that can be anticipated in clinical practice.<br>CLINICAL TREATMENT GUIDELINES<br>Selection Criteria<br>The following exclusion criteria have been utilized in case and controlled-group studies<br>of biofeedback for ADHD. The treatment protocols described in this paper have not been<br>systematically evaluated in individuals with the following characteristics:<br>• Age under 6 years,<br>• mental retardation,<br>• presence of another medical or psychiatric condition known to adversely affect<br>attention or behavioral control (e.g. anemia; hypoglycemia; diabetes; psychosis,<br>severe depression, or bi-polar disorder),<br>• history of neurological disease (including seizure; traumatic brain injury),<br>• substance abuse or dependence, and<br>• families with significant marital discord that interferes with participation in the<br>treatment process.<br>Training Protocols<br>The following protocols for EEG biofeedback training for ADHD have been supported<br>by controlled group studies. However, given recent findings indicating at least<br>two neurophysiological subtypes of ADHD, QEEG evaluation of the patient may be<br>helpful prior to initiating any of these training procedures. Such databased comparisons<br>of a patient with healthy age peers can be useful in defining the location and type of<br>EEG abnormality(ies) and contribute to the selection of a particular treatment protocol:<br>Protocol 1: SMR Enhancement/Theta Suppression<br>Electrode placement C3 or C4 (linked ear lobe reference)<br>Reward frequency 12–15 Hz<br>Inhibit frequency 4–7 or 4–8 Hz<br>Duration of behavior needed to obtain<br>reward (auditory/visual)<br>0.5 s.<br>Sampling rate 128 Hz (minimum)<br>Rate of reward Initial settings for REEG and IEEG should<br>provide approximately 15–20 auditory/<br>visual “rewards” per minute<br>Clinical goals Improve behavioral control, reduce symptoms<br>of hyperactivity and impulsivity<br>Protocol 2: SMR Enhancement/Beta-2 Suppression<br>Electrode placement C4 (linked ear lobe reference)<br>Reward frequency 12–15 Hz<br>Inhibit frequency 22–30 Hz<br>Duration of behavior needed to obtain<br>reward (auditory/visual)<br>0.5 s.<br>Sampling rate 128 Hz (Minimum)<br>Rate of reward Same as Protocol 1<br>Clinical goal Improve behavioral control, reduce symptoms<br>of hyperactivity and impulsivity<br>Protocol 3: Theta Suppression/Beta Enhancement<br>Electrode placement Cz or C3 (linked ear lobe reference)<br>FCz-PCz (ear lobe reference)<br>Cz-Pz (ear lobe reference)<br>Reward frequency 16–20 Hz<br>Inhibit frequency 4–8 Hz*<br>Duration of behavior needed to Obtain<br>reward (auditory/visual)<br>0.5 s.<br>Sampling rate 128 Hz (Minimum)<br>Rate of reward Same at Protocol 1.<br>Clinical goal Improve attention and behavioral control,<br>primarily in patients with cortical slowing.<br>*Lubar (2003) also reports a training protocol<br>that reinforces suppression of an expanded<br>“alpha” range (6–10 Hz) when<br>treating adolescents and adults with this<br>protocol. However, this has not been evaluated<br>in controlled, clinical group studies.<br>Treatment Schedules<br>Positive response has been noted with both massed (3–5 sessions per week) and spaced<br>(1 session per week) training. Sessions range in duration from 30–45 min of biofeedback<br>training. In each session, a “baseline” or “warm-up” condition is initially conducted, during<br>which no feedback is provided (2–5 minutes in duration). Subsequently, “training” segments<br>are conducted and EEG biofeedback is provided. The duration of these training segments<br>varies, often beginning with 5-min periods, gradually increasing to 9–10 min depending on<br>patient learning curves and clinical response.<br>Course of treatment is variable, ranging from 20 to 50 sessions. Calculation and<br>review of quantitative indicators of patient progress at the conclusion of each session (e.g.<br>microvolts of theta, beta-1, beta-2, or SMR; percentage of time that the patient exceeds<br>reward or inhibitory thresholds) and examination of the graphic depiction of such data is<br>critical in shaping the training protocol. Additionally, information derived from continuous<br>performance tests and behavioral rating scales is useful in evaluating patient progress.<br>Adverse Effects<br>Although no side-effects were reported in case or controlled studies, those clinical<br>researchers who have examined the effects of EEG biofeedback in conjunction with stimulant<br>medication have noted increased irritability, moodiness, and hyperactivity in patients<br>who are being treated with both types of treatments concurrently (Lubar, 2003; Monastra,<br>2003). This type of occurrence appears during the mid to late phases of biofeedback training,<br>most commonly in patients who are demonstrating improved cortical activation via<br>EEG biofeedback. Reduction in the dosage of stimulant medication (with or without introduction<br>of a “nonstimulatory” ADHD medication) has been associated with elimination<br>of this type of side effect. Other side effects (headaches; dizziness) can occur in 1–3% of<br>patients, but typically respond to a brief resting period (30 min) or consumption of food.<br>Adjunctive Treatments<br>Because ADHD has been associated with significant impairment of educational performance,<br>collaboration between the clinician and teachers is recommended, in order to<br>promote the child’s success at school during the treatment process. In the United States,<br>students with ADHD are entitled to either an Individual Education Plan (I.E.P.) or the<br>development of a 504 Accommodation Plan, depending on their need for special education<br>services. Such plans are intended to identify specific areas of functional impairment associated<br>with ADHD (e.g. disorganization, difficulty completing school assignments in class<br>and at home, and poor study skills) and define interventions to provide accommodation<br>and remediation for these problems. Whether specified via an I.E.P., an Accommodation<br>Plan, or an informal arrangement with teachers, efforts to ensure that patients are receiving<br>assistance at school typically improve classroom performance, reduce stress at home and<br>create a less conflictual learning environment for the child.<br>Parent counseling is also recommended in the treatment of children with ADHD.<br>Specifically, teaching parents strategies for systematically using reinforcement principles <br>has been shown to enhance EEG biofeedback treatments for ADHD (Monastra et al., 2002).<br>Similarly, social skills training programs, utilizing contingency management strategies (i.e.<br>point/token reward systems, time-out, and response cost) have been shown to promote<br>improved classroom functioning and the development of positive peer relationships in<br>children diagnosed with ADHD (see review by Pelham, 2002).<br>None of the traditional psychotherapeutic techniques that have been effective in treating<br>other disorders has been determined to be efficacious in the treatment of the core symptoms<br>of ADHD (i.e. inattention, hyperactivity, and impulsivity). As reported in the NIH<br>Consensus Statement on the Diagnosis and Treatment of ADHD (1998), insight-oriented<br>treatments do not exert a significant effect on these symptoms. Similarly, more recently<br>developed “cognitive-behavioral” treatments (e.g. self-monitoring, verbal self-instruction,<br>problem-solving training, self-reinforcement) have also failed to promote improvement in<br>the primary symptoms of ADHD or significant changes in the behavior or academic functioning<br>of children diagnosed with ADHD (Abikoff et al., 1988; Bloomquist, August, &amp;<br>Ostrander, 1991; Brown, Borden, Wynne, Spunt, &amp; Clingerman, 1987; National Institute<br>of Health [NIH], 1998). However, children and teens who are being subjected to parental<br>neglect or abuse will often respond favorably to individual and family therapy (as well as<br>community-based interventions from Child Protective Agencies) that address these issues.<br>REFERENCES<br>Abikoff, H., Ganeles, D., Reiter, G., Blum, C., Foley, C., &amp; Klein, R. (1988). Cognitive training in academically<br>deficient ADD-H boys receiving stimulant medication. Journal of Abnormal Child Psychology, 16(24),<br>411–432.<br>Aylward, E. E., Reiss, A. L., Reader, M. J., Singer, H. S., Brown, J. E., &amp; Denckla, M. B. (1996). Basal ganglia<br>volumes in children with attention-deficit hyperactivity disorder. Journal of Child Neurology, 11, 112–115.<br>American Psychiatric Association. (1994). Diagnostic and statistical manual of mental disorders (4th ed.).<br>Washington, DC: Author.<br>Barkley, R. A. (1998). Attention-deficit hyperactivity disorder: A handbook for diagnosis and treatment (2nd ed.).<br>New York: Guilford Press.<br>Biederman, J., Faraone, S., Keenan, K., Benjamin, J., Krifcher, B., Moore, C., et al. (1992). Further evidence for<br>family-genetic risk factors in attention deficit hyperactivity disorder: Patterns of comorbidity in probands and<br>relatives in psychiatrically and pediatrically referred samples. Archives of General Psychiatry, 49, 728–738.<br>Biederman, J., Faraone, S. V., Mick, E., Spencer, T., Wilens, T., Kiely, K., et al. (1995). High risk for attention<br>deficit hyperactivity disorder among children of parents with childhood onset of the disorder: A pilot study.<br>American Journal of Psychiatry, 152, 431–435.<br>Biederman, J., Faraone, S., Milberger, S., Guite, J., Mick, E., Chen, L., et al. (1996). A prospective 4-year<br>follow-up study of attention-deficit hyperactivity and related disorders. Archives of General Psychiatry, 53,<br>437–446.<br>Biederman, J., Keenan, K., &amp; Faraone, S. V. (1990). Parent-based diagnosis of attention deficit disorder predicts<br>a diagnosis based on teacher report. Journal of the American Academy of Child and Adolescent Psychiatry,<br>33, 842–848.<br>Benson, K., &amp; Hartz, A. J. (2000). A comparison of observational studies and randomized, controlled trials, New<br>England Journal of Medicine, 342(25), 1878–1886.<br>Bloomquist, M. L., August, G. J., &amp; Ostrander, R. (1991). Effects of a school-based cognitive-behavioral intervention<br>for ADHD children. Journal of Abnormal Child Psychology, 19, 591–605.<br>Brickenkamp, R. (1994). Test d2, Aufmerksamkeits-Belastungs-Test (8th ed.), Gottingen: Hogrefe. (Test d2.<br>Attention test)<br>Brown, R. T., Borden, K. A., Wynne, M. E., Spunt, A. L., &amp; Clingerman, S. R. (1987). Compliance with<br>pharmacological and cognitive treatment for attention deficit disorder. Journal of the American Academy of<br>Child and Adolescent Psychiatry, 26, 521–526.<br>Carmody, D. P., Radvanski, D. C., Wadhwani, S., Sabo, M. J., &amp; Vergara, L. (2001). EEG biofeedback training<br>and attention-deficit/hyperactivity disorder in an elementary school setting. Journal of Neurotherapy, 43(3),<br>5–27.<br>Castellanos, F.X. (1997). Toward a pathophysiology of attention-deficit/hyperactivity disorder. Clinical Pediatrics,<br>36, 381–393.<br>Castellanos, F. X., Giedd, J. N., Eckburg, P., Marsh, W. L., Vaituzis, A. C., Kaysen, D., et al. (1994). Quantitative<br>morphology of the caudate nucleus in attention deficit hyperactivity disorder. American Journal of Psychiatry,<br>151, 1791–1796.<br>Chabot, R. A., &amp; Serfontein, G. (1996). Quantitative electroencephalographic profiles of children with attention<br>deficit disorder. Biological Psychiatry, 40, 951–963.<br>Chabot, R. A., Merkin, H., Wood, L. M., Davenport, T. L., &amp; Serfontein, G. (1996). Sensitivity and specificity<br>of QEEG in children with attention deficit or specific developmental learning disorders. Clinical Electroencephalography,<br>27, 26–34.<br>Chabot,R. A., Orgill, A. A., Crawford, G., Harris, M. J.,&amp;Serfontein,G. (1999).Behavioral and electrophysiologic<br>predictors of treatment response to stimulants in childrenwith attention disorders, Journal of Child Neurology,<br>14(6), 343–351.<br>Chambless, D. L., &amp; Hollon, S. D. (1998). Defining empirically supported therapies. Journal of Consulting and<br>Clinical Psychology, 66(1), 7–18.<br>Clarke, A. R., Barry, R. J., McCarthy, R., &amp; Selikowitz, M. (1998). EEG analysis in attention-deficit/hyperactivity<br>disorder: A comparative study of two subtypes. Psychiatry Research, 81, 19–29.<br>Clarke, A. R., Barry, R. J., McCarthy, R., &amp; Selikowitz, M. (2001a). Electroencephalogram differences in two<br>subtypes of attention-deficit/hyperactivity disorder. Psychophysiology, 38, 212–221.<br>Clarke, A. R., Barry, R. J., McCarthy, R., &amp; Selikowitz, M. (2001b). Excess beta activity in children with<br>attention-deficit/hyperactivity disorder: An atypical electro-physiological group. Psychiatry Research, 103,<br>205–218.<br>Claude, D., &amp; Firestone, P. (1995). The development of ADHD boys: A 12 year follow-up. Canadian Journal of<br>Behavioral Science, 27, 226–249.<br>Comings, D. E., Wu, S., Chiu, C., Ring, R. H., Gade, R., Ahn, C., et al. (1996). Polygenic inheritance of Tourette<br>syndrome, stuttering, attention deficit hyperactivity, conduct, and oppositional defiant disorders: The additive<br>and subtractive effect of the three dopaminergic genes-DRD2,DBH, andDAT1. American Journal of Medical<br>Genetics, 67(3), 264–288.<br>Cook, E. H., Stein, M. A., Krasowski, M. D., Cox, N. J., Olkon, D. M., Kieffer, J. E., et al. (1995). Association<br>of attention deficit disorder and the dopamine transporter gene. American Journal of Human Genetics, 56,<br>993–998.<br>Ding, Y. S., Fowler, J., Volkow, N., Dewey, S., Wang, G. J., Logan, J., et al. (1997). Clinical drugs: Comparison<br>of the pharmacokinetics of [11 C]d-threo and 1-threo-methylphenidate in the human and baboon brain.<br>Psychopharmacology, 131, 71–78.<br>Ernst, M., Liebenauer, L. L., King, A. C., Fitzgerald, G. A., Cohen, R. M., &amp; Zametkin, A. J. (1994). Reduced<br>brain metabolism in hyperactive girls. Journal of the American Academy of Child and Adolescent Psychiatry,<br>33(6), 858–868.<br>Fuchs, T., Birbaumer, N., Lutzenberger, W., Gruzelier, J. H., &amp; Kaiser, J. (2003). Neurofeedback treatment<br>for attention-deficit/hyperactivity disorder in children: A comparison with methylphenidate. Applied Psychophysiology<br>and Biofeedback, 28(1), 1–12.<br>Gadow, K. D., &amp; Sprafkin, J. (1997). Child symptom inventory 4: Norms manual. Stony Brook, NY: Checkmate<br>Plus.<br>Giedd, J. N., Castellanos, F. X., Casey, B. J., Kozuch, P., King, A. C., Hamburger, S. D., et al. (1994). Quantitative<br>morphology of the corpus callosum in attention deficit hyperactivity disorder. American Journal of Psychiatry,<br>151, 665–669.<br>Greenberg, L.M., &amp; Dupuy, T. R. (1993). Interpretation manual for the test of variables of attention. Los Alamitos,<br>CA: Universal Attention Disorders.<br>Greenhill, L. L., Halperin, J. M., &amp; Abikoff, H. (1999). Stimulant medications. Journal of the American Academy<br>of Child and Adolescent Psychiatry, 38(5), 503–512.<br>Hartsough, C. S., &amp; Lambert, N. M. (1985). Medical factors in hyperactive and normal children: Prenatal,<br>developmental, and health history findings. American Journal of Orthopsychiatry, 55, 190–210.<br>Heywood, C., &amp; Beale, I. (2003). EEG biofeedback vs placebo treatment for attention-deficit/hyperactivity<br>disorder: A pilot study. Journal of Attention Disorders, 7(1), 41–53.<br>Hynd, G. W., Hern, K. L., Novey, E. S., &amp; Eliopulos, D. (1993). Attention deficit-hyperactivity disorder and<br>asymmetry of the caudate nucleus. Journal of Child Neurology, 8, 339–343.<br>Hynd, G. W., Semrud-Clikeman, M., Lorys, A. R., &amp; Novey, E. S. (1990). Brain morphology in developmental<br>dyslexia and attention deficit disorder/hyperactivity. Archives of Neurology, 47, 919–926.<br>Kaiser, D. A., &amp; Othmer, S. (2000). Effect of neurofeedback on variables of attention in a large multi-center trial.<br>Journal of Neurotherapy, 4(1), 5–28.<br>Kim, B.-N., Lee, J.-S., Shin, M.-S., Cho, S.-C., &amp; Lee, D.-S. (2002). Regional cerebral perfusion abnormalities<br>in attention deficit/hyperactivity disorder: Statistical parametric mapping analysis. European Archives of<br>Psychiatry and Clinical Neuroscience, 252, 219–225.<br>Kaufman, A., &amp; Kaufman, N. (1990). K-BIT: Kaufman brief intelligence test manual. Circle Pines, MN: American<br>Guidance Service.<br>Lahey, B. B., Pelham, W. E., Stein, M. A., Loney, J., Trapani, C., Nugent, K., et al. (1998). Validity of DSM-IV<br>attention-deficit/hyperactivity disorder for younger children. Journal of the American Academy of Child and<br>Adolescent Psychiatry, 37(7), 695–702.<br>LaVaque, T. J., Hammond, D. C., Trudeau, D., Monastra, V. J., Perry, J., &amp; Lehrer, P. (2002). Template for<br>developing guidelines for the evaluation of the clinical efficacy of psychophysiological interventions. Applied<br>Psychophysiology and Biofeedback, 27(4), 273–281.<br>Levy, R., Hay, D. A., McStephen, M., Wood, C., &amp; Waldman, I. (1997). Attention-deficit hyperactivity disorder:<br>A category or a continuum? Genetic analysis of a large-scale twin study. Journal of the American Academy<br>of Child and Adolescent Psychiatry, 36, 737–744.<br>Linden, M., Habib, T., &amp; Radojevic, V. (1996). A controlled study of the effects of EEG biofeedback on cognition<br>and behavior of children with attention deficit disorder and learning disabilities. Biofeedback and Self-<br>Regulation, 21(1), 35–49.<br>Lou, H. C., Henriksen, L., &amp; Bruhn, P. (1990). Focal cerebral hypoperfusion in children with dysphasia and/or<br>attention deficit disorder. Archives of Neurology, 41(8), 825–829.<br>Lubar, J. F. (2003) Neurofeedback for the management of attention deficit disorders. In M. S. Schwartz &amp;<br>F. Andrasik (Eds.), Biofeedback: A practitioner’s guide (3rd ed., pp. 409–437). New York: Guilford Press.<br>Lubar, J. O., &amp; Lubar, J. F. (1984). Electroencephalographic biofeedback of SMR and beta for treatment of<br>attention deficit disorders in a clinical setting. Biofeedback and Self Regulation, 9, 1–23.<br>Lubar, J. F., &amp; Shouse, M. N. (1976). EEG and behavioral changes in a hyperkinetic child concurrent with training<br>of the sensorimotor rhythm (SMR): A preliminary report. Biofeedback and Self Regulation, 1, 293–306.<br>Lubar, J. F., Swartwood, M. O., Swartwood, J. N., &amp; Timmermann, D. L. (1995). Quantitative EEG and auditory<br>event-related potentials in the evaluation of attention-deficit disorder: Effects of methylphenidate and implications<br>for neurofeedback training. Journal of Psychoeducational Assessment Monographs, (Special ADHD<br>Issue). 143–160.<br>Mann, C., Lubar, J., Zimmerman, A., Miller, C., &amp; Nuenchen, R. (1992).Quantitative analysis of EEG in boys with<br>attention-deficit-hyperactivity disorder: Controlled study with clinical implications. Pediatric Neurology, 8,<br>30–36.<br>Mannuzza, S., Gittelman-Klein, R., Bessler, A., Malloy, P., &amp; LaPadula, M. (1993). Adult outcome of hyperactive<br>boys: Educational achievement, occupational rank, and psychiatric status. Archives of General Psychiatry,<br>50, 565–576.<br>Mannuzza, S., Klein, R. G., Bessler, A., Malloy, P., &amp; LaPadula, M. (1998). Adult psychiatric status of hyperactive<br>boys grown up. American Journal of Psychiatry, 155, 493–498.<br>Mannuzza, S., Klein, R. G., Bonagura, N., Malloy, P., Giampino, H., &amp; Addalli, K. A. (1991). Hyperactive boys<br>almost grown up: Replication of psychiatric status. Archives of General Psychiatry, 48, 77–83.<br>McCarney, S. B. (1989). Attention Deficit Disorders Evaluation Scale. Columbia, MO: Hawthorne Educational<br>Services, Inc.<br>Monastra, V. J. (2003). Clinical applications of electroencephalographic biofeedback. In M. S. Schwartz &amp;<br>F. Andrasik (Eds.), Biofeedback: A practitioner’s guide (3rd ed., pp. 438–463). New York: Guilford Press.<br>Monastra, V. J. (2004). Parenting children with ADHD: Lessons that medicine cannot teach. Washington, DC:<br>American Psychological Association.<br>Monastra, V. J., Lubar, J. F., &amp; Linden, M. (2001). The development of a quantitative electroencephalographic<br>scanning process for attention deficit-hyperactivity disorder: Reliability and validity studies. Neuropsychology,<br>15, 136–144.<br>Monastra, V. J., Lubar, J. F., Linden, M., VanDeusen, P., Green, G., Wing, W., et al. (1999). Assessing attention<br>deficit hyperactivity disorder via quantitative electroencephalography: An initial validation study.<br>Neuropsychology, 13(3), 424–433.<br>Monastra, V. J., Monastra,D.M., &amp; George, S. (2002). The effects of stimulant therapy, EEG biofeedback, and parenting<br>style on the primary symptoms of attention-deficit/hyperactivity disorder. Applied Psychophysiology<br>and Biofeedback, 27(4), 231–249.<br>Mostofsky, S. H., Reiss, A. L., Lockhart, P., &amp; Denckla, M. B. (1998). Evaluation of cerebellar size in attention deficit<br>hyperactivity disorder. Journal of Child Neurology, 13, 434–439.<br>Murphy, K., &amp; Barkley, R. A. (1996). Attention deficit hyperactivity disorder adults: Comorbidities and adaptive<br>impairments. Comprehensive Psychiatry, 37, 393–401.<br>National Institutes of Health. (1998). Consensus statement on the diagnosis and treatment of attention deficit/<br>hyperactivity disorder. Bethesda, MD: Author.<br>Nuwer, M. (1997).Assessment of digital EEG, quantitative EEG, and EEG brain mapping: Report of the American<br>Academy of Neurology and the American clinical Neurophysiology Society, Neurology, 49, 277–292.<br>Pelham, W. E. (2002). Psychosocial interventions for ADHD. In P. S. Jensen &amp; J. R. Cooper (Eds.). Attention<br>deficit hyperactivity disorder: State of the science: Best Practices (pp. 12-1–12-36), Kingston, NJ: Civic<br>Research Institute.<br>Pelham, W. E., Gnagy, E. M., Greenslade, K. E., &amp; Milich, R. (1992). Teacher ratings of DSM-III-R symptoms<br>for the disruptive behavior disorders. Journal of the American Academy of Child and Adolescent Psychiatry,<br>31, 210–218.<br>Pelham, W. E., &amp; Murphy, H. H. (1986). Attention deficit and conduct disorder. In M. Hersen (Ed.), Pharmacological<br>and behavioral treatment: An integrative approach (pp. 108–148). New York: Wiley.<br>Pelham, W. J., &amp; Smith, B. H. (2000) Prediction and measurement of individual responses to ritalin by children<br>and adolescents with ADHD. In L. Greenhill &amp; B. Osman (Eds.), Ritalin: Theory and patient management<br>(2nd ed.). New York: Mary Ann Liebert.<br>Rossiter, T. R., &amp; LaVaque, T. J. (1995). A comparison of EEG biofeedback and psycho-stimulants in treating<br>attention deficit/hyperactivity disorders. Journal of Neurotherapy, 1, 48–59.<br>Roth, S. R., Sterman, M. B., &amp; Clemente, C. C. (1967). Comparison of EEG correlates of reinforcement, internal<br>inhibition, and sleep. Electroencephalography and Clinical Neurophysiology, 23, 509–520.<br>Semrud-Clikeman, M., Filipek, P. A., Biederman, J., &amp; Steingard, R. (1994). Attention-deficit hyperactivity disorder:<br>Magnetic resonance imaging morphometric analysis of the corpus callosum. Journal of the American<br>Academy of Child and Adolescent Psychiatry, 33, 875–881.<br>Sieg, K. G., Gaffney, G. R., Preston, D. F., &amp; Hellings, J. A. (1995). SPECT brain imaging abnormalities in<br>attention deficit hyperactivity disorder. Clinical Nuclear Medicine, 20(1), 55–60.<br>Silberg, J., Rutter, M., Meyer, J., Maes, H., Hewitt, J., Simonoff, E., et al. (1996). Genetic and environmental<br>influences on the covariation between hyperactivity and conduct disturbance in juvenile twins. Journal of<br>Child Psychology and Psychiatry and Allied Disciplines, 37, 803–816.<br>Smalley, S. L., Bailey, J. N., Palmer, C. G., Cantwell, D. PO., McGough, J. J., Del-Homme, M. A., et al. (1998).<br>Evidence that the dopamine D4 receptor is a susceptibility gene in attention deficit hyperactivity disorder.<br>Molecular Psychiatry, 3, 427–430.<br>Sterman, M. B. (1996). Physiological origins and functional correlates of EEG rhythmic activities: Implications<br>for self-regulation. Biofeedback and Self-Regulation, 21(1), 3–49.<br>Sterman, M. B. (2000). Basic concepts and clinical findings in the treatment of seizure disorders with EEG operant<br>conditioning. Clinical Electroencephalography, 31, 45–55.<br>Sterman, M. B., &amp;Wywricka,W. (1967). EEG correlates of slep: Evidence for separate forebrain substrates. Brain<br>Research, 6, 143–163.<br>Sterman, M. B., Wywricka, W., &amp; Roth, S. R. (1969). Electrophysiological correlates and neural substrates of<br>alimentary behavior in the cat. Annals of the New York Academy of Science, 157, 723–739.<br>Still, G. F. (1902). Some abnormal psychical conditions in children. Lancet, 1, 1008–1012, 1077–1082, 1163–<br>1168.<br>Swanson, J. M., McBurnett, K., Christian, D. L., &amp; Wigal, T. (1995). Stimulant medication and treatment of<br>children with ADHD. In T. H. Ollendick &amp; R. J. Prinz (Eds.), Advances in clinical child psychology (Vol.<br>17, pp. 265–322). New York: Plenum Press.<br>Tansey, M. (1993). Ten-year stability of EEG biofeedback results for a hyperactive boy who failed the fourth<br>grade perceptually impaired class. Biofeedback and Self-Regulation, 18(1), 33–38.<br>Thompson, L., &amp; Thompson, M. (1998). Neurofeedback combined with training in metacognitive strategies:<br>Effectiveness in students with ADD. Applied Psycho-physiology and Biofeedback, 23(4), 243–263.<br>Tredgold, A. F. (1908). Mental deficiency (amentia). New York: W. Wood.<br>Volkow, N. D., Ding, Y. S., Fowler, J. S., Wang, G. J., Logan, J., Gatley, J. S., et al. (1995). Is methylphenidate<br>like cocaine? Studies on their pharmacokinetics and distribution in the human brain. Archives of General<br>Psychiatry, 52, 456–463.<br>Weiss, G., &amp; Hechtman, L. (1993). Hyperactive children grown up (2nd ed.). New York: Guilford Press.<br>Welner, Z., Welner, A., Stewart, M., Palkes, H., &amp; Wish, E. (1977). A controlled study of siblings of hyperactive<br>children. Journal of Nervous and Mental Disease, 165, 110–117.<br>Willcut, E. G., Pennington, B. F., &amp; DeFries, J. C. (2000). Twin study of the etiology of comorbidity between<br>reading disability and attention-deficit/hyperactivity disorder. American Journal of Medical Genetics, 96,<br>293–301.<br>Wolraich, M. L., Hannah, J. N., Pinnock, T. Y., Baumgaertel, A., &amp; Brown, J. (1996). Comparison of diagnostic<br>criteria for attention-deficit hyperactivity disorder in a country wide sample. Journal of the American Academy<br>of Child and Adolescent Psychiatry, 35, 319–324.<br>Wywricka, W., &amp; Sterman, M. B. (1968). Instrumental conditioning of sensorimotor cortex EEG spindles in the<br>waking cat. Physiology and Behavior, 3, 703–707.<br>Zametkin, A. J., Nordahl, T. E., Gross, M., King, A. C., Semple, W. E., Rumsey, J., et al. (1990). Cerebral<br>glucose metabolism in adults with hyperactivity of childhood onset. New England Journal of Medicine, 323,<br>1361–1366.</p> <br>
                        <p></p>
                        <a class="menu" href="http://www.alertfocus.com/evidence/eegbiofeedbackadhd.php?print=1"><img src="eegbiofeedbackadhd.php_files/news.gif" alt="Print it" align="absmiddle" border="0" height="21" width="21"><strong> 
                        Printer-friendly version</strong></a> 
                        <p>
                           </p>
                           
                              
                        <h4 style="display:inline;"> <br>
                          Related content 
                          <hr size="1" width="100%">
                        </h4>
                          
                            <table border="0" cellpadding="0" cellspacing="0" width="100%">
                            
                            </table>
                            <table border="0" cellpadding="10" cellspacing="0" width="100%">
                              <tbody><tr>
                                
                            <td class="smallfont3" valign="top">  
                              <div class="otstup2">
                                      <li style="color:e4e4e4" type="square"><a href="http://www.bfe.org/protocol/pro12eng.htm" class=" menu_gray smallfont2">Olympic Peak Performance Training with Biofeedback</a>                              
                                  </li></div>
                                     
                              <div class="otstup2">
                                      <li style="color:e4e4e4" type="square"><a href="http://www.eegmedia.com/cbsclip.htm" class=" menu_gray smallfont2">CBS TV news on ADD</a>                              
                                  </li></div>
                                     
                              <div class="otstup2">
                                      <li style="color:e4e4e4" type="square"><a href="http://isnr.org/uploads/Comprehensive%20Neurofeedback%20Bibliography.pdf" class=" menu_gray smallfont2">Neurofeedback Bibliography</a>                              
                                  </li></div>
                                     </td>
                              </tr>
                            </tbody></table>
                            </td>
                        </tr>
                      </tbody></table></td> 
                    
  <td valign="top"> 
                      
                      <table align="center" border="0" cellpadding="0" cellspacing="0" width="180">                            
                            <tbody><tr> 
                              <td align="left" bgcolor="#ffffff" height="20">
                              <img src="eegbiofeedbackadhd.php_files/5.jpg" height="50" width="180"></td> 
                            </tr> 
                            <tr> 
                              <td align="left" bgcolor="#cccccc">
                              <img src="eegbiofeedbackadhd.php_files/1px.gif" height="1" width="180"></td> 
                            </tr> 
                            <tr> 
                              <td align="left"><table border="0" cellpadding="1" cellspacing="0" width="100%">
                                <tbody><tr>
                                  <td>                                       <table align="center" border="0" cellpadding="0" cellspacing="0" width="100%">
                                        <tbody><tr>
                                          <td>
                                            <table align="center" border="0" cellpadding="0" cellspacing="0" width="100%">
                              <tbody><tr>
                  <td valign="top" width="22">
<img src="eegbiofeedbackadhd.php_files/crumb.png" align="absMiddle" border="0" height="11" width="19"> 
				</td>
<td valign="top">
<a href="http://www.bfe.org/protocol/pro12eng.htm" class="crumbs">Olympic Peak Performance Training with Biofeedback</a>
</td>

                </tr>
                <tr>
                  <td colspan="2" bgcolor="cccccc"><img src="eegbiofeedbackadhd.php_files/1px.gif" height="1" width="1"></td>
                </tr>
                              <tr>
                  <td valign="top" width="22">
<img src="eegbiofeedbackadhd.php_files/crumb.png" align="absMiddle" border="0" height="11" width="19"> 
				</td>
<td valign="top">
<a href="http://www.eegmedia.com/cbsclip.htm" class="crumbs">CBS TV news on ADD</a>
</td>

                </tr>
                <tr>
                  <td colspan="2" bgcolor="cccccc"><img src="eegbiofeedbackadhd.php_files/1px.gif" height="1" width="1"></td>
                </tr>
                              <tr>
                  <td valign="top" width="22">
<img src="eegbiofeedbackadhd.php_files/crumb.png" align="absMiddle" border="0" height="11" width="19"> 
				</td>
<td valign="top">
<a href="http://isnr.org/uploads/Comprehensive%20Neurofeedback%20Bibliography.pdf" class="crumbs">Neurofeedback Bibliography</a>
</td>

                </tr>
                <tr>
                  <td colspan="2" bgcolor="cccccc"><img src="eegbiofeedbackadhd.php_files/1px.gif" height="1" width="1"></td>
                </tr>
                                                          </tbody></table>
                                        </td></tr>
                                        <tr>
                                          <td bgcolor="f5f5f5"><img src="eegbiofeedbackadhd.php_files/1px.gif" height="1" width="1"></td>
                                        </tr>
                                        <tr>
                                          <td>&nbsp;</td>
                                        </tr>
                                      </tbody></table>
                                      </td>
                                </tr>
                                <tr>
                                  <td>
                                  
                                    <br>
 <table cellpadding="0" cellspacing="0" width="100%">
   <tbody><tr>
     <td colspan="2">
       <p><b class="smallfont otstup2"></b> </p></td>
   </tr>
   </tbody></table>
   </td>
                                </tr>
                              </tbody></table>
                               </td> 
                            </tr>
 
                        </tbody></table></td> 
                    </tr> 
                   
                </tbody></table></td> 
            </tr> 
           
        </tbody></table></td> 
    </tr> 
   
</tbody></table> 
<table bgcolor="#d8d8d8" border="0" cellpadding="0" cellspacing="0" width="100%">   
    <tbody><tr> 
      <td>
      <img src="eegbiofeedbackadhd.php_files/zero.gif" height="1" width="190">
      </td> 
    </tr>    
</tbody></table> 

<table bgcolor="#efefef" border="0" cellpadding="0" cellspacing="0" width="100%">    
    <tbody><tr bgcolor="#ffffff"> 
      <td bgcolor="#efefef">
      <img src="eegbiofeedbackadhd.php_files/zero.gif" height="40" width="8">
      </td> 
      
    <td bgcolor="#efefef" height="40"> <strong><font color="#000000"> 
      <table border="0" cellpadding="0" cellspacing="0" width="100%">
        <tbody><tr> 
          <td width="200"> <strong>www.<font color="#000000">A</font>lert<font color="#000000">F</font>ocus.com<br>
            </strong><span class="smallfont3">© Copyright 2004, Gary Ames</span></td>
          <td class="tool"> <a href="http://www.alertfocus.com/about/terms.php">Terms</a> | <a href="http://www.alertfocus.com/about/index.php">About</a> 
            &nbsp;</td>
          <td class="tool">&nbsp;</td>
        </tr>
      </tbody></table>
      </font></strong></td> 
      <td bgcolor="#efefef">&nbsp;</td> 
    </tr> 
    <tr bgcolor="#d8d8d8"> 
      <td colspan="3" height="1"><img src="eegbiofeedbackadhd.php_files/zero.gif" height="1" width="200"></td> 
    </tr> 
   
</tbody></table> 


</titleeeg></body></html>